 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
FATAL ACUTE PANCREATITIS
IN A PATIENT CHRONICALLY TREATED WITH CANDESARTAN
Christopher J Gill, Anne E Jennings, Jeffrey B Newton, and David E
Schwartz
To request full article click here.
OBJECTIVE: To summarize a case of acute pancreatitis in a patient receiving the angiotensin II receptor blocker (ARB) candesartan.
CASE SUMMARY: A previously healthy 75-year-old white man presented with acute pancreatitis complicated by anuric renal failure, respiratory failure, circulatory collapse, and died within 24 hours despite resuscitation efforts. He had been receiving candesartan 32 mg/day for more than one year with no apparent adverse effects.
DISCUSSION: In recent years, angiotensin-converting enzyme (ACE) inhibitors have been linked with sporadic cases of acute pancreatitis. Recent case reports suggest a similar association between pancreatitis and the related drug class of ARBs. Animal data indicate that the renin-angiotensin system plays an important role in pancreatic hemodynamics and exocrine function and is activated in the setting of acute pancreatitis. Because both ARBs and ACE inhibitors affect angiotensin II, we hypothesize that a common pathophysiologic mechanism might apply to both ARB- and ACE inhibitor-induced pancreatitis.
CONCLUSIONS: Although acute pancreatitis appears to be a rare complication of both ARBs and ACE inhibitors, the catastrophic outcome in this case mandates that clinicians be aware of this adverse effect. Further research into the role of the renin-angiotensin system in the pathogenesis of acute pancreatitis appears warranted.
J Pharm Technol 2005;21:79-82.
To request full article click here.
|
|
|
||
|
